Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways

Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways

Summary: The anti-CD20 monoclonal antibodies rituximab and obinutuzumab differ in their mechanisms of action, with obinutuzumab evoking greater direct B cell death. To characterize the signaling processes responsible for improved B cell killing by obinutuzumab, we undertook a phosphoproteomics appro...

Full description

Bibliographic Details
Main Authors: Jennifer Edelmann, Arran D. Dokal, Emma Vilventhraraja, Karlheinz Holzmann, David Britton, Tetyana Klymenko, Hartmut Döhner, Mark Cragg, Andrejs Braun, Pedro Cutillas, John G. Gribben
Format: Article
Language:English
Published: Elsevier 2021-02-01
Series:iScience
Subjects:
immunology
systems biology: proteomics
cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004221000572

Internet

http://www.sciencedirect.com/science/article/pii/S2589004221000572

Similar Items